These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15840884)

  • 1. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient.
    Tonini G; Vincenzi B; Santini D; Olzi D; Lambiase A; Bonini S
    J Natl Cancer Inst; 2005 Apr; 97(8):606-7. PubMed ID: 15840884
    [No Abstract]   [Full Text] [Related]  

  • 2. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Rodriguez NA; Ascaso FJ
    J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
    [No Abstract]   [Full Text] [Related]  

  • 3. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
    Dranko S; Kinney C; Ramanathan RK
    Clin Colorectal Cancer; 2006 Sep; 6(3):224-5. PubMed ID: 17026793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient].
    Ramírez-Soria MP; España-Gregori E; Aviñó-Martínez J; Pastor-Pascual F
    Arch Soc Esp Oftalmol; 2008 Nov; 83(11):665-8. PubMed ID: 19006019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 6. Blepharitis induced by epidermal growth factor receptor-targeting therapy.
    Ulusakarya A; Gumus Y; Delmas-Marsalet B; Machover D
    Am J Clin Oncol; 2006 Oct; 29(5):531. PubMed ID: 17023793
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab-associated pulmonary toxicity.
    Chua W; Peters M; Loneragan R; Clarke S
    Clin Colorectal Cancer; 2009 Apr; 8(2):118-20. PubMed ID: 19739274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blepharitis and trichomegaly induced by cetuximab.
    Criado PR; Lima AA
    An Bras Dermatol; 2010; 85(6):919-20. PubMed ID: 21308323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
    Chong G; Cunningham D
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
    Bambury R; McCaffrey JA
    Clin Colorectal Cancer; 2009 Oct; 8(4):235. PubMed ID: 19822516
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutrophilic eccrine hidradenitis induced by cetuximab.
    Turan H; Kaya E; Gurlevik Z; Erdem H; Oktay M
    Cutan Ocul Toxicol; 2012 Jun; 31(2):148-50. PubMed ID: 22034841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.
    Kaechele V; von Wichert G; Adler G; Seufferlein T
    Oncology; 2008; 74(3-4):123-6. PubMed ID: 18708729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.
    Eames T; Kroth J; Flaig MJ; Ruzicka T; Wollenberg A
    Acta Derm Venereol; 2010 Mar; 90(2):202-3. PubMed ID: 20169314
    [No Abstract]   [Full Text] [Related]  

  • 16. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumatosis intestinalis after cetuximab-containing chemotherapy for colorectal cancer.
    Yoon S; Hong YS; Park SH; Lee JL; Kim TW
    Jpn J Clin Oncol; 2011 Oct; 41(10):1225-8. PubMed ID: 21835823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eye complications of cetuximab therapy.
    Melichar B; Nemcová I
    Eur J Cancer Care (Engl); 2007 Sep; 16(5):439-43. PubMed ID: 17760931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.